Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN FE 1.5/30 vs DEMULEN 1/50-21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration; alters endometrial receptivity. Norethindrone also decreases ovarian estrogen production.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years (if no known contraindications and have achieved menarche),Off-label: Dysmenorrhea, menstrual irregularities, endometriosis-associated pain, hirsutism
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label use)
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
Ethinyl estradiol terminal half-life is approximately 13-17 hours; norethindrone terminal half-life is approximately 7-10 hours. Steady-state is reached within 5-10 days.
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Ethinyl estradiol: primarily CYP3A4 metabolism with first-pass hepatic and intestinal metabolism; undergoes conjugation (glucuronidation and sulfation). Norethindrone: extensively metabolized via reduction, glucuronidation, and sulfation; CYP3A4 also involved.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, with hydroxylation by CYP3A4 and conjugation via glucuronidation and sulfation. Ethynodiol diacetate is rapidly deacetylated to norethindrone, which is metabolized by reduction and conjugation, with CYP3A4 as a minor pathway.
Ethinyl estradiol and norethindrone are primarily excreted via renal (urine) and fecal routes. Approximately 40-50% of ethinyl estradiol is excreted renally as metabolites, with 20-30% in feces. Norethindrone metabolites are excreted ~50-70% renally and 20-30% fecally. Less than 5% is excreted unchanged.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Ethinyl estradiol: ~97-98% bound, primarily to albumin (70%) and sex hormone-binding globulin (SHBG). Norethindrone: ~61-63% bound, primarily to albumin and SHBG.
Ethinylestradiol: 97-98% bound to serum albumin (primarily) and SHBG; ethynodiol diacetate: >95% bound to albumin and SHBG.
Ethinyl estradiol: Vd approximately 2.5-4 L/kg; norethindrone: Vd approximately 4-5 L/kg. Distribution into breast milk and body fat is notable.
Ethinylestradiol: 2.8-4.3 L/kg (extensive tissue distribution, including breast and reproductive tissues); ethynodiol: 1.5-2.0 L/kg.
Ethinyl estradiol: ~40-50% due to first-pass metabolism; norethindrone: ~50-65% with first-pass metabolism. Food may increase bioavailability.
Oral: Ethinylestradiol 38-48% (first-pass metabolism); ethynodiol diacetate ~60% (rapid hydrolysis to active norethindrone).
Contraindicated in patients with renal impairment or renal disease.
No dose adjustment required for mild-moderate renal impairment. Avoid use in severe renal impairment or dialysis due to potential fluid retention and electrolyte disturbances.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). Use with caution in Child-Pugh class A, consider alternative therapy.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Use in mild hepatic impairment not recommended.
Not indicated for use in pediatric females before menarche. For postmenarchal pediatric patients, dosage same as adults: one tablet orally once daily for 21 days, then 7 placebo tablets.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults. Safety and efficacy established in post-pubertal females.
Not indicated for use in postmenopausal women. Safety and efficacy not established in geriatric population.
Not indicated after menopause. Risk of thromboembolic events outweighs benefits in women over 35 who smoke or have cardiovascular risk factors.
Cigarette smoking increases risk of serious cardiovascular events (stroke, myocardial infarction, thromboembolism) from combined oral contraceptives. Risk increases with age and number of cigarettes smoked, particularly in women >35 years. Advise not to smoke.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Increased risk of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction, especially in smokers >35 years, hypertension, obesity, diabetes, hyperlipidemia, or migraine with aura. Monitor for undiagnosed abnormal genital bleeding, liver disease, hypertension, depression, migraine, carbohydrate/lipid effects, hereditary angioedema, chloasma, retinal thrombosis, gallbladder disease, and anaphylactic reactions. Discontinue if jaundice, vision changes, or severe headache occurs.
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking increases cardiovascular risk, especially in women over 35,Increased risk of hypertension, gallbladder disease, and hepatic neoplasia,Risk of retinal thrombosis; discontinue if unexplained vision loss occurs,May cause fluid retention; use with caution in conditions affected by fluid retention,May induce cholestatic jaundice; discontinue if jaundice develops,May cause carbohydrate and lipid metabolism changes
Current or history of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction, or transient ischemic attack; known coagulation disorders; valvular heart disease with complications; uncontrolled hypertension; diabetes with vascular involvement; headache with focal neurological symptoms (migraine with aura) in women >35; estrogen-sensitive cancer (e.g., breast cancer); hepatic tumors or active liver disease; undiagnosed abnormal uterine bleeding; pregnancy; hypersensitivity to components; cigarette smoking in women >35 years; use with hepatitis C drug regimens containing ombitasvir/paritaprevir/ritonavir (with or without dasabuvir).
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Active liver disease (e.g., acute viral hepatitis, decompensated cirrhosis),Hypersensitivity to any component
Grapefruit or grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects; avoid concurrent consumption. No specific dietary restrictions otherwise. Iron supplement in active tablets may cause GI upset; take with food to reduce irritation.
No specific food interactions. Oral contraceptives may increase caffeine levels; limit caffeine intake if side effects like jitteriness occur. Grapefruit and grapefruit juice do not significantly affect this medication.
No increased risk of birth defects observed with oral contraceptives; avoid use in pregnancy due to potential for fetal harm and lack of necessity. First trimester: no consistent evidence of malformations. Second/third trimester: may cause fetal harm from estrogenic effects; discontinue if pregnancy occurs.
First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Second and third trimesters: Avoid due to risk of fetal harm, including masculinization of female fetus with progestins; also associated with increased risk of neonatal jaundice and liver dysfunction.
Small amounts of ethinyl estradiol and norethindrone pass into breast milk; M/P ratio not established. May reduce milk quantity and quality. Not recommended for breastfeeding mothers until weaning complete to avoid infant exposure to sex hormones.
Small amounts of ethinyl estradiol and ethynodiol diacetate are excreted in breast milk. M/P ratio not established. Estrogen-progestin combinations may reduce milk production and alter milk composition; use during breastfeeding is generally not recommended. Consider alternative contraception.
Contraindicated in pregnancy; no dose adjustment applicable. Pharmacokinetic changes in pregnancy (increased clearance) may reduce efficacy if used inadvertently; use alternative contraception.
Not applicable as use is contraindicated during pregnancy. No pharmacokinetic studies have been conducted to recommend dose adjustments.
Contains norethindrone 1.5 mg and ethinyl estradiol 30 mcg; low estrogen dose, suitable for women with estrogen sensitivity; iron supplement (ferrous fumarate 75 mg) in last 7 tablets helps prevent iron deficiency; missed pill protocol: if one tablet missed, take as soon as remembered; if two missed in week 1 or 2, take two the next day and two the day after; if two missed in week 3 or three or more missed at any time, discard pack and start new pack next day, use backup contraception for 7 days.
DEMULEN 1/50-21 is a monophasic oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Use with caution in patients over 35 who smoke due to increased cardiovascular risk. Monitor for breakthrough bleeding, especially in the first three cycles. Consider drug interactions with rifampin, anticonvulsants, and broad-spectrum antibiotics. Administer at the same time daily to maintain efficacy. The 21-day regimen requires a 7-day pill-free interval. Instruct to start on first day of menses or first Sunday after onset.
Take one tablet daily at the same time, preferably after an evening meal to reduce nausea.,The last 7 tablets (brown) contain iron; do not skip them even if bleeding occurs.,If you miss a pill, refer to the missed pill instructions in the package insert.,Use backup contraception (e.g., condoms) if pills are missed or if you start a new pack late.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first 3 months.,Report severe abdominal pain, chest pain, shortness of breath, severe headache, or vision changes immediately.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,This medication does not protect against sexually transmitted infections (STIs).
Take one tablet daily at the same time, starting on the first day of your menstrual period or the first Sunday after your period begins.,Swallow tablet whole with water, with or without food.,After finishing all 21 tablets, wait 7 days before starting a new pack. You will have a withdrawal bleed during this time.,If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours, take the missed tablet and use backup contraception for 7 days.,Seek emergency medical care for symptoms of blood clots (sudden severe headache, chest pain, shortness of breath, leg pain/swelling), stroke (sudden numbness/weakness, slurred speech), or liver problems (yellowing skin/eyes, dark urine).,Avoid smoking while taking this medication, especially if over age 35, due to increased risk of cardiovascular events.,Inform your healthcare provider about all other medications (including over-the-counter drugs, herbal supplements like St. John's Wort) as they may reduce contraceptive efficacy.,This medication does not protect against HIV or other sexually transmitted infections.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN FE 1.5/30 vs DEMULEN 1/50-21, answered by our medical review team.
LARIN FE 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration; alters endometrial receptivity. Norethindrone also decreases ovarian estrogen production.. DEMULEN 1/50-21 is a Combination Oral Contraceptive that works by DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN FE 1.5/30 and DEMULEN 1/50-21 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN FE 1.5/30 is: One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets.. The standard adult dose of DEMULEN 1/50-21 is: 1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN FE 1.5/30 and DEMULEN 1/50-21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN FE 1.5/30 is classified as Category C. No increased risk of birth defects observed with oral contraceptives; avoid use in pregnancy due to potential for fetal harm and lack of necessity. First trimester: no consistent e. DEMULEN 1/50-21 is classified as Category C. First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.